Imaging characteristic of dual-phase 18F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer’s disease and mild cognitive impairment
- 1.2k Downloads
We investigated dual-phase 18F-florbetapir (AV-45/Amyvid) PET imaging for the concomitant detection of brain perfusion deficits and beta-amyloid deposition in patients with Alzheimer’s disease (AD) and amnestic mild cognitive impairment (MCI), and in cognitively healthy controls (HCs).
A total of 82 subjects (24 AD patients, 44 MCI patients and 14 HCs) underwent both dual-phase 18F-AV-45 PET and MRI imaging. Dual-phase dynamic PET imaging consisted of (1) five 1-min scans obtained 1 – 6 min after tracer injection (perfusion 18F-AV-45 imaging, pAV-45), and (2) ten 1-min scans obtained 50 – 60 min after tracer injection (amyloid 18F-AV-45 imaging). Amyloid-negative MCI/AD patients were excluded. Volume of interest analysis and statistical parametric mapping of pAV-45 and 18F-AV-45 images were performed to investigate the perfusion deficits and the beta-amyloid burden in the three study groups. The associations between Mini-Mental State Examination (MMSE) scores and global perfusion deficits and amyloid deposition were investigated with linear and segmental linear correlation analyses.
HCs generally had normal pAV-45 findings, whereas perfusion deficits were evident in the hippocampus, and temporal, parietal and middle frontal cortices in both MCI and AD patients. The motor-sensory cortex was relatively preserved. MMSE scores in the entire study cohort were significantly associated with the degree of perfusion impairment as assessed by pAV-45 imaging (r = 0.5156, P < 0.0001). 18F-AV-45 uptake was significantly higher in AD patients than in the two other study groups. However, the correlation between MMSE scores and 18F-AV-45 uptake in MCI patients was more of a binary phenomenon and began in MCI patients with MMSE score 23.14 when 18F-AV-45 uptake was higher and MMSE score lower than in patients with early MCI. Amyloid deposition started in the precuneus and the frontal and temporal regions in early MCI, ultimately reaching the maximum burden in advanced MCI.
Our results indicate that brain perfusion deficits and beta-amyloid deposition in AD follow different trajectories that can be successfully traced using dual-phase 18F-AV-45 PET imaging.
KeywordsDual-phase scan Perfusion deficits Amyloid 18F-Florbetapir (AV-45/Amyvid) Alzheimer’s disease Dementia Mild cognitive impairment
We thank Avid Radiopharmaceuticals Inc. (Philadelphia, PA, USA) for providing the precursor for the preparation of 18F-florbetapir.
Compliance with ethical standards
This study was carried out with financial support from the National Research Program for Biopharmaceuticals, National Science Council, Taiwan (MOST 103-2314-B-182A-009, 104-2314-B-182A-083-MY2, 103-2325-B-182A-009) and grants from the Research Fund of Chang Gung Memorial Hospital (CMRPG390793).
Conflicts of Interest
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study. In addition, the next of kin or guardians of AD and MCI patients also gave their written informed consent if the patients could not comprehend the study protocol or they could not sign their name clearly.
- 1.McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. Washington, DC: American Psychiatric Association.Google Scholar
- 33.Pagani M, De Carli F, Morbelli S, Öberg J, Chincarini A, Frisoni G, et al. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study. NeuroImage Clin. 2015;7:34–42.CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S, et al. Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease. Brain Imaging Behav. 2012;6:568–83.CrossRefPubMedPubMedCentralGoogle Scholar